Bilyana Georgieva

Bilyana Georgieva

Auto-generated profile, based on publicly available information

Bilyana Georgieva

Department of Paediatrics, Medical University, Sofia, Bulgaria;Aleksandrovska Hospital, Sofia, Bulgaria

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 January 2026 in American Journal of Pediatrics
Verified
Journal Article
Closed access
Polina Yordanova KostovaPolina Yordanova Kostova
Polina Yordanova Kostova
Julieta HristovaJulieta Hristova
Julieta Hristova
BGBilyana Georgieva
Bilyana Georgieva
GPGuergana Petrova
Guergana Petrova
MMMileva Mileva
Mileva Mileva
Introduction: Airway remodelling in children with severe recurrent episodes of bronchial obstruction starts very early, from preschool age – a period in which the diagnosis of asthma is not yet confirmed. Assessing these early structural changes presents a challenge in clinical practice. Due to the limitations of invasive methods, reliable noninvasive markers of these changes are sought. Galectin-3 (Gal-3), a regulator of inflammatory and fibrotic processes, and Krebs von den Lungen-6 (KL-6), a marker of alveolar epithelial damage, are considered as indicators of lung remodelling. Methods: Forty-eight children were studied: 26 children under 4 years of age with recurrent episodes of wheezing (RW) and 22 with cystic fibrosis (CF). Children with RW were divided into two subgroups: those with a low frequency (≤3 episodes/year) and those with a high frequency (>6 episodes/year) of bronchoobstructive symptoms. CF patients were stratified according to genotype (ΔF508 homozygous or heterozygous), and all underwent computed tomography (HRCT). Serum Gal-3 and KL-6 levels were measured by the ELISA method. The correlation between Gal-3 and KL-6 and clinical severity in children with recurrent wheezing at preschool age, and between Gal-3 and KL-6 and radiologically confirmed structural lung changes in children with cystic fibrosis, was assessed. Results: Elevated Gal-3 levels were found in children with RW from infancy. Although the differences in median Gal-3 levels did not reach statistical significance in the two RW subgroups, children with a high frequency of wheezing were 1.76 times more likely to have elevated Gal-3 (>26 ng/mL) compared to those with a low frequency of RW (p = 0.02). In CF, Gal-3 levels were significantly higher in children with confirmed structural lung disease on HRCT compared to those without pathological changes (38.35 vs. 11.63 ng/mL, p = 0.001). The highest Gal-3 values were found in ΔF508 homozygous patients with bronchiectasis. KL-6 levels remained within the normal range for the pediatric population across all groups and did not correlate with the frequency of bronchoobstructive manifestations, genotype, or CT findings. Conclusion: Galectin-3 is a reliable biomarker for pediatric pulmonology practice, reflecting early pulmonary changes in children with frequent recurrent bronchoobstructive episodes and a risk of persistent manifestations, and it correlates with structural damage in cystic fibrosis patients. KL-6 has no diagnostic value in the early stages of pulmonary pathology.